کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5667065 | 1591749 | 2016 | 4 صفحه PDF | دانلود رایگان |
- Switch from unboosted protease inhibitor to an RPV/FTC/TDF-based single-tablet regimen among HIV-1-infected patients is proposed.
- The switch is safe and associated with a reduction in plasma triglycerides and plasma cholesterol.
- Decrease in cART-related costs and non-cART patient management is highlighted.
This study aimed to evaluate the efficacy, tolerability and potential savings of combined antiretroviral therapy (cART) simplification from an unboosted protease inhibitor (PI) regimen with atazanavir or fosamprenavir to a single-tablet regimen (STR) based on rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) among HIV-1-infected patients with HIV-1 RNA <50 copies/mL. This was a retrospective, multicentre, open-label, 12-week trial. Plasma HIV-1-RNA levels, CD4+ cell counts, cholesterol, triglycerides, bilirubin, glycaemia, creatinine and physical examination were performed at baseline and at scheduled follow-up. All patient costs were calculated and were estimated for 52 weeks of therapy. Fifty-one patients were enrolled [28 male (54.9%)]. At baseline, 30 patients (58.8%) were treated with FTC/TDF, 20 (39.2%) with abacavir/lamivudine and 1 (2.0%) with lamivudine/zidovudine. Thirty-three patients (64.7%) received atazanavir. All patients maintained HIV-RNA <50 copies/mL; the median CD4+ cell count remained stable. Mean triglycerides decreased from 124âmg/dL (range, 39-625) at enrolment to 108.7âmg/dL (range, 39-561) at study end (Pâ=â0.25). At baseline, mean cholesterol was 172.8â±â38.1âmg/dL and decreased to 161.9â±â38.6âmg/dL (Pâ=â0.038); likewise, median total bilirubin decreased from 1.07âmg/dL (range, 0.2-4.7) to 0.6âmg/dL (range, 0.13-3.1) (Pâ<0.001). cART-related annual cost reduction with a STR was â¬3155.47 per patient (â24%). Non-cART patient management expenses were â¬402.68 vs. â¬299.10 for atazanavir or fosamprenavir and STR regimens, respectively. Switching to RPV/FTC/TDF from an unboosted PI in virologically suppressed HIV-infected patients is safe and is associated with a reduction in triglycerides, cholesterol and cART-related costs.
Journal: International Journal of Antimicrobial Agents - Volume 48, Issue 5, November 2016, Pages 551-554